

Spectrum of late, non-stroke manifestations of small vessel disease

Teaching Courses

STROKE TC 2

Hall D Date: SATURDAY, OCTOBER 31, 2015 From: 14:30 To: 18:00 45 min

Michael Brainin, MD FESO FAHA
Professor in Clinical Neurology
Danube University Krems, Austria

XXII World Congress Neurology, Santiago, Chile, Oct31-Nov 5, 2015

Rol

Consultancy and speakers honoraria	Grants to University and Royalties
Allergan	European Commission Public Health
 Boehringer 	• European Research Foundation FP7
• Bayer	Life Science Foundation Krems
Ever Neuro Pharma	Ever Neuro Pharma
• Takeda	Boehringer, Takeda
• Pfizer	Cambridge Univ Press
• Medtronic	Wiley Blackwell
• Nestlec	World Stroke Organsiation
	European Academy of Neurology

Spectrum of late, non-stroke manifestations of small vessel disease

- In this lecture, the attendee will learn about
- The large variations of frontal lobe syndromes due to SMV
- Apathia, irritability, euphoria are the hall marks (dysexecutive syndrome)
- Neuropsychological assessment
- Some neuropathological facts
- Current trials focusing on prevention

- Due to the differing locations of smd there is a wide spectrum.
- Often the clinical signs become apparent in later stages of the disease
- The main signs are behavioural disoders
- Of these, dysexecutive signs are most frequent




Table 11.1 Manifestations of Prefrontal Damage (Frontal Lobishness)

Table 11.1 Planifestations of French	
Tactlessness	*Irritability
Poorly restrained behavior	Disinhibition
Decreased social concern	Coarseness
Jocularity	Hyperkinetic
Facetiousness	Hypokinetic
Witzelsucht	Flare with anger
Moria	Puerile (silly) attitude
Boastfulness	Disinhibition of social graces
Grandiosity	Inappropriate sexual advances
Decreased intiative	Sexual exhibitionism
Decreased attentiveness	Lewd conversation
Forgetfulness	Erotic behavior
Poor memory	*Euphoria
Indifference	Poor planning ability
	Diminished concern for the future
*Apathy	Capriciousness
Shallow effect	Loss of abstract attitude
Lack of spontaneity	Loss of esthetic sense
Abulia	Impulsiveness
Asthenia	Distractability
Akinesia	Stimulus bound
Deterioration of work quality	Concreteness
Depression	Perseveration
Morose discontent	Restlessness
Delusions: Grandiosity (strength, wealt	n, intelligence)
Nihilism	
Paranoia	
Hypochondriasis	and the second s

*The unholy triad of frontal behavior disorder suggested by Geschwind (1977).


Bensons' Neurology of Thinking and ,frontal lobishness'

Unholy triad of frontal behaviour disorder (Geschwind, 1977)


- Apathy
- Irritability
- Euphoria

67 year old sportive motor journalist

- Compulsive iteration of words/sentences, unaware that he feels he has to comment or iterate sentences with trivial contents, partly not adequate
- Response to the next syndrome Neurology, 1988; 38:1225-7
- Agitation, generally in high spirits
- Spreads good mood, jocularity, add times inappropriate charming remarks to nurses
- But highly irritable about changes of lunch/dinner times
- Neuropsychological tests, esp. for memory and attention are normal.



JB, ID 101788754, 67ys, orthostatic syncope, neuro normal



Cognition – test instruments

- 1) Short neuropsychological test-battery including (20min) Can be administrated by non-neuropsychologists
 - Montreal Cognitive Assessment (MOCA)
 - Trail making test A and B
 - Digit-Span forward and backward
- 2) More detailed test-battery (1-1.5h) for centres with neuropsychologists (substudy) to describe in detail the neuropsychological profile of the participants

includes: tests for alertness, reaction time, verbal fluency, verbal memory, visual spatial perception, visual memory...

Cognition – test instruments


Montreal Cognitive Assessment (MOCA)

Short screening instrument for mild vascular cognitive impairment Administration time approximately 10 min

include: - attention and concentration

- executive functions
- memory
- language
- visuoconstructional skills
- conceptual thinking
- calculations
- orientation

Not available in Bulgarian and Lithuanian No costs, written permission is requested




Cognitive decline

- 0.8-2 points decline on MMSE / year
- 10-32% had cognitively declined after 1 year from baseline (3 months post-stroke)
- cognitive decline increases with recurrent stroke

detection of cognitive decline depends on the cognitive

tests used



Cognitive testing in patients with first ischemic stroke with MMSE and MoCA at baseline, after 3 and 6 months


Popovic et al. 2007. J Neurol Sci 257: 185-93


Cognition – test instruments

Trail making test A and B:

Timed paper-and-pencil test, testing the domains: executive functions (cognitive flexibility), speed of processing

Administration time approximately 5 min





Cognition – test instruments

Digit-Span forward and backward:

Subject has to repeat strings of digits of increasing length in same order or reverse order.

Testing the domains: working memory, attention, executive functions

Administration time approximately 5 min

Training for short neuropsychological test battery

Short training (1h) is necessary for standardization and scoring Best is self-testing and answers to questions afterward (online)

Vascular Cognitive Impairment Harmonization Standards

National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards

Hachinski V et al.

Stroke 2006, published 17 August 2006, doi:10.1161/01.STR.0000237236.88823.47

30 minutes

- Semantic fluency (animal naming)
- Phonemic fluency (word association)
- Digital symbol coding (from the WAIS)
- Verbal learning test
- Depression scale (CESDS)
- Neuropsychiatric inventory
- MMSE, Trail making


5 minutes

- Montreal Cognitive Assessment subsets:
- 5 word memory task (registration, recall, recognition)
- 6 item orientation
- 1 letter phonemic fluency

- Definitions:
- Lack of consensus on how to operationalize established criteria
- Lack of comparability between studies
- If threshold for inclusion is chosen as 1 SD difference a large number of cases result whereas 2SD difference result in lower numbers
- Plus/minus subjective memory complaints

Mild cognitive impairment after stroke spares memory

- Mild cognitive impairment (no dementia) at 3 months varies from 17% - 66% depending on the criteria used.
- RR 1.5 2.1 compared to stroke free controls
- more characterized by executive dysfunction, psychomotor speed slowing than by memory problems
- 41% had executive dysfunction at 3 months poststroke




Patterns of cognitive impairment excluding subjects with preexisting cognitive decline (79 strokes, 87 nonstrokes)

Srikanth et al. 2003. Stroke 34:1136-43

Lacunar stroke and cognitive impairment

- 58 75% had cognitive deficits within 1 month poststroke;
 60% at 2 years
- dementia 11% at 1-3 years poststroke and 15% at 9 years
- leukoaraiosis increases the risk of dementia after lacunar stroke. 16% vs 2% had dementia at 1 month; 22% vs 3% at 25 months; mainly executive functions are affected.
- silent lacunes are associated with poorer executive performance
- silent lacunes in the thalamus and in the basal ganglia are indepent predictors of cognitive decline

Influence of silent brain infarcts on cognitive decline




The presence of a new silent brain infarcts more than doubles the risk of dementia; hazard ratio 2.3 (95% CI: 1.1-4.7).

Mean change in memory performance, psychomotor speed, and global cognitive function among participants with and those without silent brain infarcts on MRI at baseline (1995-1996) and at follow-up (1999-2000), after adjustment for age, sex, level of education, and interval between neuropsychological tests

Vermeer S et al 2003. N Engl J Med 348:1215-22

Silent subcortical lacunes are associated with poor executive functions



Total Number of Lacunes

Correlation between number of lacunes and executive performance (R²=0.20; P<0.0001)

Carey et al 2008. Stroke 39:397-402


 From the Framingham study a significant decline of - 3.7 points (comparable to – 1.3 SD) in the mean MMSE was found in 74 stroke patients tested within 6 months of stroke onset compared to stroke free controls (no change)

- Americans aged 50+ from the Health and Retiremnt Study 1998-2008
- N=20,567 participants
- N= 1189 strokes, survived
- N= 385 strokes, deceased
- 10 word list delayed recall
- 5-item Likert scale and 16 item version IQ code
- Results: 0.71 SD reduction in similar period than Framingham study


Wang Q et al. Long-term rate of change in memory functioning before and after stroke onset. Stroke 2012

- Even prestroke, future stroke pateints experience a long period of memory decline, a decline that continues for years after stroke
- Prestroke memory decline is most likely an early sign of cerebrovascular disease
- Lower memory performance increases vulnerability to clinically manifest stroke
- Individuals with a very high memory scores may have a better cognitive reserve and be able to to sustain an acute ischemic stroke without memory impairment.

Trajectory of memory score for stroke survivors (n=1189) vs stroke decedents (n=385) vs stroke-free cohort members (n=15 766) during entire follow-up.



Cognitive impairment prior to stroke correlates with poststroke cognitive decline



Changes in MMSE score between baseline and 1 year after stroke against baseline MMSE

Appelros & Andersson 2006. Eu J Neurol 13:491-5

Factors significantly associated with pre-stroke dementia.

Associated factor	No. of studies	Strength of association
Demographic factors		
Female sex	7	++
Low education	5	++
FH	1	++++
Vascular risk factors		
Diabetes	6	+
AF	5	+
IHD	3	+
Previous TIA	4	+
Hypertension	6	+
Stroke factors		
Previous stroke	6	++
Multiple infarcts	3	+
Brain imaging factors		
MTL atrophy	3	++++
Leukoaraiosis	3	+++

Adapted from Pendlebury and Rothwell [12]. += OR 1-2; ++= OR 2-3; +++= OR 3-4; ++++= OR >4.

FH = family history; IHD = ischaemic heart disease; TIA = transient ischaemic attack; MTL = medial temporal lobe.

Brain 2011: 134; 3716-3727

Factors significantly associated with post-stroke dementia.

Associated factor	No. of studies	Strength of association
Demographic factors		
Female sex	24	+
Caucasian	3	_
Low education	11	++
Vascular risk factors		
Diabetes	19	+
AF	13	++
Stroke factors		
Hemorrhagic S.	9	+
Dysphasia	7	+++
Left hemisphere	17	+
Brainstem	9	_
Number of strokes		
Previous stroke	10	+
Multiple strokes	9	++
Recurrent stroke	4	++
Stroke complications		
HI episodes	2	++
Incontinence	7	++++
Acute confusion	2	++
Early seizures	1	++++
Abnormal EEG	1	++
Brain imaging factors		
Leukoaraiosis	7	++
Atrophy	5	++
MTL atrophy	2	++

Adapted from Pendlebury and Rothwell [12]. += OR 1-2; ++= OR 2-3; +++= OR 3-4; ++++= OR >4; -= OR <1.


Hemorrhagic S. = hemorrhagic stroke; HI = hypoxic ischaemic episodes; EEG = electroencephalogram; MTL = medial temporal lobe.

Recurrent stroke and risk of dementia

The rate of dementia is at least twice as high after recurrent stroke.

Hospital-based

Population



Recurrent stroke and risk of dementia

The rate of dementia is at least twice as high after recurrent stroke.

Study Dementia/ Prevalence 95% CI p value for Diagnostic total heterogeneity (years) method Hospital-based, recurrent stroke, including pre-stroke dementia 54-2-80-5 DSM IV 33/49 67.3% 66 Zhou et al70 45/113 39.8% 30-8-48-8 68 DSM IV 21-0-39-0 DSM III Pohjasvaara et al3 30/100 30.0% 71 recurrent (41%) Gorelick et al43* 33-5-49-5 61/147 41.5% 72 DSM III 29-6-53-1 169/409 41.3% < 0.0001 Hospital-based, any (first or recurrent) stroke, including pre-stroke dementia 25-2-37-5 DSM IV Klimkovicz et al72 69/220 31.4% 66 Zhou et al70 23-0-31-4 68 118/434 27.2% DSM IV Barba et al54 24-2-35-5 69 DSM IIIR 75/251 29.9% de Koning et al^{78,79} 18-9-28-5 71/300 23.7% DSM IIIR anv (27%) de Koning et al⁸⁰ 20-8-37-0 35/121 28-9% 70 DSM IV Desmond et al7 22-2-30-3 71 DSM IIIR 119/453 26-3% Pohiasvaara et al3 21.5-29.5 DSM III 115/451 25.5% 71 Tang et al76 15-3-24-7 DSM IV 56/280 20.0% 70 Henon et al² 23-4-38-6 ICD10 44/142 31.0% Total 24-3-28-7 702/2652 26.5% 0.07 Hospital-based, first-ever stroke, including pre-stroke dementia Klimkowicz et al72 14-9-27-2 66 DSM IV 36/171 21.1% Zhou et al7 18-2-27-3 68 DSM IV 73/321 22.7% first (23%) Pohjasvaara et al3 19-7-28-7 85/351 24.2% 71 DSM III 194/843 23.0% 21-4-24-7 0.71 Hospital-based, any (first or recurrent) stroke, excluding pre-stroke dementia Klimkowicz et al72 16-7-28-4 66 DSM IV 44/195 22.6% Zhou et al70 17-6-25-6 68 DSM IV 87/403 21.6% any (20%) Barba et al54 16-7-27-5 69 DSM IIIR 50/226 22.1% de Koning et al80 29/115 25.2% 17-3-33-2 70 DSM IV Tang et al76 no pre-stroke 11-1-19-9 DSM IV 40/258 15.5% 71 Inzitari et al53 57/339 16.8% 12.8-20.8 71 ICD10 Pohjasvaara et al³ 78/414 18-8% 15.1-22.6 71 DSM III dementia Andersen et al⁴⁷ 18-8-33-3 72 **MDRS** 37/142 26-1% Henon et al² 22.8% 15.5-30.1 ICD10 29/127 18-2-22-5 451/2219 20.3% 0.09 Hospital-based, first-ever stroke, excluding pre-stroke dementia Censori et al48 15/110 7-2-20-0 13.6% NINDS A first (12%); no pre Gur et al44 11.1% 6.7-15.4 73 DSM IIIR Total stroke dementia 37/309 9-6-14-4 0.51 12.0% Population-based, first-ever stroke, including pre-stroke dementia Srikanth et al87 11/88 5-6-19-4 12.5% DSM IV Population-based, first-ever stroke, excluding pre-stroke dementia 9/74 12.2% 4.7-19.6 ◀ DSM III 79 Kokmen et al82 68/971 7.0% 5-4-8-6 NA Records first (7%); no pre-4-8-10-0 0.18 77/1045 7.4% stroke dementia 25 30 35 40 45 50 55


Population

Stroke and dementia are tightly related

- 1 patient in 10 already has dementia when stroke occurs,
- 1 patient in 10 will develop dementia after a first-ever stroke
- 1 in 3 in patients will develop dementia with stroke recurrence.

Interaction: Stroke and Alzheimer

Mechanisms: Alzheimer + stroke




Neuropathological changes in VaD/VCI:

- Lacunar infarcts
- Microinfarcts
- White matter changes
- Hippocampal atrophy and sclerosdis
- Overlap with AD pathology
 - Amyloid plaques
 - Neurofibrillary tangles

Figure Ageing related Vascular disease (hypertension, diabetes, atherosclerosis) Cerebral Amyloid associated Microangiopathy Microangiopathy Arteriolosclerosis Arteriolosclerosis Cell-molecular events in NV unit ↑ eNOS activity Cytokines / Growth factors Progression EC activation ↑ BBB leakiness ↑ Perivascular macrophages (CD68 + cells) Perivascular oedema ↑ Astrogliosis/ ↑ ECM Parenchymal changes CAA related bleeds GM lacunes and WM lacunes and and microinfarcts microinfarction microinfarcts ↑ Aβ accumulation, ↓ SMC, wall rupture ↓ Vascular tone † Hypoxic state (HIF1α, VEGF) † PVS ↓ Oligodendrocyte

Post-stroke cognitive impairment

Neuronal volumes in hippocampal subregions CA1, CA2, and entorhinal cortex Layer V (ECV).



All PS: all poststroke subjects; PSND: poststroke nondemented; PSD: delayed poststroke dementia; VaD: vascular dementia; mixed: mixed Alzheimer, and vascular dementia; AD: Alzheimer disease.

Asterisks indicate significantly different to controls (black) or PSND (gray; P<0.05). Dots indicate trend to significance (P<0.01).


Post-stroke cognitive impairment

- Neuropathological data show that post-stroke cognitive function correlate with CA-2 neuronal volumes
- CAMCOG total scores and CAMCOG memory scores
- "selective hippocampal neuronal atrophy or shrinkage is an important substrate for dementia afte rstroke in the absence of neurodegenerative pathology"

Post-stroke cognitive impairment

 "These findings provide evidence of a vascular basis for hippocampal neurodegeneration in delayed PSD and VaD"

Post-stroke patients compared to healthy controls: show less MTL activation indicating tertiary, delayed onset mechanisms of vascular neurodegeneration




Difference in MTL activation between healthy controls (n = 22) and stroke patients (n = 28) during 0-back minus 2-back contrast. Healthy controls showed significantly more MTL activation than patients during the 0-back minus 2-back contrast, thresholded at P = 0.001 uncorrected.

Snaphaan L et al. Brain 2009; 132: 1882

Mofification of life-style factors: prevents post-stroke cognitive decline?


- The FINGER trial has shown that lifestyle modification through multi-domain interventions prevents cogntive decline in persons with a high vascular risk and risk of mild cogntive impairment
- The ASPIS trial used similar interventions in post-stroke patients and was neutral. Perhaps the occurrence of the dysexecutive syndrome was less in the intervention group (n.s.)

Dementia and AD: importance of life-long exposure to multiple factors



ASPIS - <u>Aus</u>trian <u>Polyintervention Study to</u> Prevent Cognitive Decline after <u>Ischemic Stroke</u> Identification number at clinicaltrials.gov: NCT01109836.





Brainin M et al. Int J Stroke. 2013 Nov 10. doi: 10.1111/ijs.12188.

Intervention Goals

Strict blood pressure treatment: Treatment goal BP <140/90mmHg on at least 75% of all measurements, for patients with diabetes 130/85 mmHg.

Physical activity: moderate or vigorous physical activity 3-5 times/ week

Diet: BMI <25, weight reductions and maintenance of at least 5% weight loss during the first year in obese individual. Dietary goals according to nutrient intake and food intake

Smoking cessation in smokers

Pharmacological treatment according to ESO guideline.

Lowering of cholesterol with lipid-lowering drugs (preferably statins). LDL-cholesterol <70 mg/dl

Antithrombotic therapy (ATT): most important is continuous ATT. ATT will be used in all patients except in those eligible for oral anticoagulation.

Patients with diabetes mellitus: optimal pharmacological treatment according to current guidelines of the Austrian Association for Diabetes

Definition of Cognitive Decline

Composite z-scores for 5 domains:


- individual test score differences between baseline and 24 month
- Standardization using standard deviations of a control population


Criteria for cognitive decline at 24month:


- Significant decline in at least 2 of 5 domains
- Critical level for the decline in a single domain is set using standard normal distribution (alpha level 0.05 and corrected according to binomial function for the probability of a decline in 2 out of 5 domains)

Neuropsychological Test Battery


- Stroop Color Word Interference Test (15 min)
- Trailmaking Test (Parts A and B) (5 min)
- Luria Auditory Verbal Learning Test immediate recall (6 min)
- Benton Visual Retention Test (reproduction after 10 s) (10 min)
- Letter Fluency Test (semantic and phonemic) (6 min)
- 5-Points Test (Hamasch) revised (5 min)
- Digit Span (forward and backwards)(6 min)
- Luria Auditory Verbal Learning Test delayed recall (
- Block Design Test (15 min)
- ADAS-cog








MOSAIC: visual-spatial



The percentage of persons with cognitive decline according to domains did not differ between groups.

Brainin M et al. Int. J. Stroke 2015, Matz et al. Stroke 2015

Persons with cognitive decline (≥2 domains)



Recommendations for future research.

- Harmonize cognitive outcome measures for RCTs
- Sample size
- High risk population
- Follow up period
- Biomarkers, Imaging
- Interventions that make a difference